蛋白酪氨酸激酶6抑制剂的研究进展

Progress in the studies on PTK6 inhibitors

蛋白酪氨酸激酶6(PTK 6)是一种细胞内的非受体型Src相关酪氨酸激酶。在对乳腺癌、卵巢癌、鼻咽癌、非小细胞肺癌和前列腺癌的研究中发现,PTK6可以诱导肿瘤细胞的增殖、侵袭和转移,PTK6在上述类型肿瘤的发展过程中发挥着重要作用,因此,抑制PTK6的活性可有效地控制肿瘤的发生发展。PTK6是一个非常有价值的潜在的癌症治疗靶点。本文主要对近年来关于PTK6抑制剂的研究进展做一综述。

Protein tyrosine kinase 6（ PTK6）,also known as breast tumor kinase（ BRK）,is an intracellular tyrosine kinase distantly related to the Src-family of tyrosine kinases. The studies of breast cancer,ovarian cancer,nasopharyngeal carcinoma,and non-small cell lung cancer and prostate cancer,had shown that PTK6 can induce tumor proliferation,migration and invasion. PTK6 plays an important role in the process of the development of tumor. Therefore,inhibiting the activity of PTK6 can effectively control the evolution of tumors. So PTK6 is a very valuable potential cancer treatment target. This reviewmainly describes the recent development of PTK6 inhibitors.